RecruitingPhase 2NCT06667908
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Principal Investigator
- Johnson & Johnson Enterprise Innovation Inc. Clinical TrialJohnson & Johnson Enterprise Innovation Inc.
- Intervention
- JNJ-90301900(drug)
- Enrollment
- 130 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- University of Connecticut Health Center, Farmington, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- University of Miami, Miami, Florida, United States
- Orlando Health Cancer Institute, Orlando, Florida, United States
- Emory University Winship Cancer Institute, Atlanta, Georgia, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- NYU Langone Health, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- FirstHealth of the Carolinas, Pinehurst, North Carolina, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Oregon Health And Science University, Portland, Oregon, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06667908 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →